Co-localization of histamine and norepinephrine in sympathetic ganglia and exocytosis of endogenous histamine from cardiac sympathetic nerve endings of macaca mulatto monkey

AIM To provide the evidence about localization, biosynthesis, metabolism and release of histamine from the cardiac sympathetic nerve terminals, and endogenous sympathetic histamine could inhibit itsel frelease from the nerve terminal through the presynaptic histamine H3 receptor. METHODS Using double-labeled immunohistochemistry to observe the co-localization of histamine and NE in the superior cer-vical ganglia (SCG) of macaca mulatto monkey; Different-speed centrifugation to obtain the cardiac sympathetic nerve terminal model (the cardiac synaptosomes), spectrofluorometer and ELISA techniques to detect the release of histamine from the cardiacsynaptosomes. RESULTS ( 1 ) The coexistence of histamine and norepinephrine immunoreactivities was identified in the same neuron within SCG of macaca mulatto monkey. (2) Depolarization of macaca mulatto monkey cardiac synaptosomes with 50 mmol/L potassium caused the release of endogenous histamine,     

赞美——心理上的强心剂

赞美,即鼓励、强化,是行为科学中的一个概念。它可以给平凡的生活带来希望,可以把世间的噪音化为音乐。赞美对人类心灵的重要性,好比植物依赖于阳光,没有     

新型强心药MCI—154

ＭＣＩ－１５４为ＣＩ－９１４和ＣＩ－９３０等哒嗪酮磷酸二酯酶抑制剂的新衍生物，具有较强的强心和扩血管作用，其优点是无显著的正性频率作用，并可改善心脏缺血区的收缩功能，提高心肌收缩蛋白系统对Ｃａ＾２＋敏感性为其主要强心作用机制，已被列入新型强心药物－钙增敏剂的主要成员，本文介绍其化学结构，药理作用及其作用机制的最新研究结果。     

Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism

Objective： To investigate the anti-inflammatory effect of erythropoietin （EPO） pretreatment on cardiomyocytes exposed to hypoxialreoxygenation injury （H/R） and explore the possible mechanism.
Methods： The cultured neonatal rats＇ ventricular cardiomyocytes were divided randomly into 4 groups, control group （C group）, EPO pretreatment group （E group）, EPO and pyrrolidine dithiocarbamate （PDTC） pretreatment group （EP group） and PDTC pretreatment group （P group）. After 24 hours＇ pretreatment, the cardiomyocytes were exposed to H/R. After pretreatment and H/R, the expression of tumor necrosis factor- α （TNF- α ） gene in all the groups was detected by RT-PCR and Western blot. The nuclear factor- κ B （NF- κB） activity was detected by electrophoretic mobility shift assay （EMSA） and the inhibitor- κB α （Ⅰ- κB α） protein level was detected by Western blot.
Results： The decrement of Ⅰ- κB a protein and the increasing NF- KB activity were found in cardiomyocytes pretreated with EPO before H/R compared to other groups （t=3.321, 4.183, P〈0.01）. However, after H/R, NF- κB activity and expression of TNF- α gene were significantly reduced, Ⅰ- κB a protein expression was increased in cardiomyocytes of E group compared to other groups （t=-3.425, 3.687, 3.454, P〈0.01）. All theses changes caused by EPO pretreatment were eliminated by the intervention of PDTC （an antagonist to NF- κB） during pretreatment.
Conclusions： EPO pretreatment can inhibit the activation of NF- κB and upregulation of TNF- α gene in cardiomyocytes exposed to H/R through a negative feedback of NF- κB signaling pathway, and thus produces the anti-inflammatory effect. This might be one of the ways EPO produces the anti-inflammatory effect.     

急性肺水肿18例观察与抢救

急性肺水肿在临床发病急骤，病情进展迅速，严重威胁着病人的生命。护理人员要做到严密观察，及时发现，及时处理。2002年1月-2003年1月，我院共收治急性肺水肿患者18例，取得了满意的效果，现报告如下。     

非洋地黄类强心剂合并酚妥拉明治疗慢性肺心病心衰30例

我院应用非洋地黄类强心剂合并酚妥拉明治疗慢性肺源性心脏病 (肺心病 ) ,心力衰竭Ⅱ～Ⅲ度患者 30例 (称治疗组 ) ,与同期应用一般常规治疗 38例 (称对照组 )作对比观察 ,结果治疗组收到了满意疗效 ,现报道如下 :1　临床资料1 1　一般资料我院自 1998年 10月以来 ,在收治的慢性肺心病并发心衰患者中抽取 30例 (治疗组 )和 38例 (对照组 )作治疗统计对照。两组病例年龄均在 5 5～ 70岁 ,肺心病病史 6年以上 ,其原发病有慢性支气管炎、支气管扩张、支气管哮喘并发肺气肿 ,全部病例符合内科学肺心病诊断标准[1]1 2　治疗方法对照组 :采用常规…     

小剂量氯胺酮在15例重型失血性休克患者中的麻醉效果

失血性休克病人的病情十分危急，须争分夺秒采取果断手术等措施，麻醉选择更是至关重要，特别是在基层医院，设备条件落后，很多不具备插管条件，麻醉选择受限。选择良好的麻醉方法，达到手术医师的麻醉要求，以及时救治患者至关重要。我院于2000年以来，采用小剂量氯胺酮麻醉用于15例重型失血性休克手术病人，获得满意效果，现报道如下：     

2005年欧洲心脏病学会急性心力衰竭诊断和治疗指南介绍（5）

4,9围手术期AHF围手术期AHF通常与心肌缺血有关,过去10年人口老龄化使这一问题更为突出。在至少一个心血管危险因素(年龄>70岁,心绞痛,既往MI,充血性HF,治疗室性心律失常,治疗糖尿病,活动耐量受限,高     

心肌泰治疗小儿病毒性心肌炎的疗效观察

为观察心肌泰治疗小儿病毒性心肌炎的临床疗效,对收治的111例病毒性心肌炎患儿进行控制感染、抗病毒、营养心肌及对症治疗,在此基础上对63例病毒性心肌炎患儿给予口服心肌泰3～4周,患儿临床症征有显著改善,心肌泰治疗小儿病毒性心肌炎,疗效满意.